4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxybenzoic acid | 313701-93-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxybenzoic acid
• 英文别名: 4-(2,5-dimethylpyrrol-1-yl)-2-hydroxybenzoic acid
• CAS: 313701-93-8
• 化学式: C₁₃H₁₃NO₃
• mdl: MFCD01874283
• 分子量: 231.25
• InChiKey: WAYCNXGAKFXIKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.153
• 拓扑面积：
  62.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  、 16-(Diethylamino)-11-imino-14-oxa-3,10-diazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(21),2,4,6,8,12,15(20),16,18-nonaene-12-carbonitrile 、 双酚A 、 、 sodium dodecyl benzene sulfonate 、 、 乙酸乙酯 反应 0.08h， 以to obtain a color particle dispersion (NB-2)的产率得到4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxybenzoic acid
  参考文献：
  名称：

  Decoloring type heat sensitive image recording material

  摘要：

  一种褪色型热敏图像记录材料，包括透明支撑和设置在其上的热敏层。热敏层包含颜色颗粒和亲水性粘合剂。颜色颗粒分散在亲水性粘合剂中。颜色颗粒是由亚甲基蓝类染料与酚类显影剂反应形成的。热敏层基本上不含褪色剂颗粒。热敏层可以通过热能作用于图像记录材料，使颜色颗粒与亲水性粘合剂反应，使颗粒褪色，且褪色状态在室温下保持。还公开了一种通过褪色热敏材料记录图像的方法。

  公开号：

  US05407890A1

文献信息

• [EN] PYRROL-1 -YL BENZOIC ACID DERIVATES USEFUL AS MYC INHIBITORS<br/>[FR] DÉRIVÉS D'ACIDE PYRROL-1-YL-BENZOÏQUE UTILES EN TANT QU'INHIBITEURS DE MYC
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2014071247A1

  公开（公告）日：2014-05-08

  The present invention provides compounds of Formula (I-A), (I-B), and (I-C), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting Myc (e.g., c-Myc) activity. The present invention further provides methods of using the compounds described herein for treating Myc-mediated disorders (e.g., cancer and other proliferative diseases). The present invention also provides assays for identifying Myc inhibitors.

  本发明提供了式(I-A)、(I-B)和(I-C)的化合物、药用可接受的盐及其药用组合物。本发明的化合物可用于抑制Myc（例如，c-Myc）活性。本发明进一步提供了使用所述化合物治疗Myc介导的疾病（例如，癌症和其他增殖性疾病）的方法。本发明还提供了用于识别Myc抑制剂的检测方法。
• Anti-infective compounds
  申请人：Brodin Priscille

  公开号：US20110178077A1

  公开（公告）日：2011-07-21

  The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.

  本发明涉及小分子化合物及其在治疗细菌感染，特别是结核病方面的用途。
• [EN] EphA4 INHIBITORS AS NEUROPROTECTIVE AGENTS<br/>[FR] INHIBITEURS D'EPHA4 EN TANT QU'AGENTS NEUROPROTECTEURS
  申请人：UNIV HONG KONG SCIENCE & TECHN

  公开号：WO2015007222A1

  公开（公告）日：2015-01-22

  Provided is the discovery of the role of EphA4 signaling in neurodegenerative disorders involving β-amyloid induced neurotoxicity such as Alzheimer's Disease. New therapeutic methods, therapeutic agents, and kits for treating diseases caused or exacerbated by overactivated EphA4 signaling are provided. Also provided are methods for identifying additional compounds as therapeutic agents useful for treating conditions involving overly active EphA4 signaling.

  提供了EphA4信号在涉及β-淀粉样蛋白诱导的神经毒性等神经退行性疾病中的作用发现，如阿尔茨海默病。提供了用于治疗由过度活化的EphA4信号引起或加重的疾病的新疗法、治疗剂和工具。还提供了用于识别额外化合物作为治疗剂，对治疗涉及过度活跃的EphA4信号的条件有用的方法。
• PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US20150291521A1

  公开（公告）日：2015-10-15

  The present invention provides compounds of Formula (I-A), (I-B), and (I-C), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting Myc (e.g., c-Myc) activity. The present invention further provides methods of using the compounds described herein for treating Myc-mediated disorders (e.g., cancer and other proliferative diseases). The present invention also provides assays for identifying Myc inhibitors.

  本发明提供了公式(I-A)、(I-B)和(I-C)的化合物，其药学上可接受的盐以及其制药组合物。本发明的化合物可用于抑制Myc（例如c-Myc）的活性。本发明还提供了使用本文所描述的化合物治疗Myc介导的疾病（例如癌症和其他增殖性疾病）的方法。本发明还提供了用于鉴定Myc抑制剂的检测方法。
• Anti-EphA4 antibody
  申请人：EISAI R&D MANAGEMENT CO., LTD.

  公开号：US10428140B2

  公开（公告）日：2019-10-01

  It is intended to provide an anti-EphA4 antibody or an EphA4-binding fragment thereof which is capable of binding to EphA4 and inhibiting the binding between EphA4 and its ligand, and a pharmaceutical composition comprising the anti-EphA4 antibody or the EphA4-binding fragment thereof as an active ingredient. A mouse anti-EphA4 antibody having binding affinity for EphA4 was obtained, and the sequences of complementarity-determining regions (CDRs) of the mouse anti-EphA4 antibody were identified. This allowed for preparation of a humanized antibody comprising the CDR sequences of the mouse anti-EphA4 antibody in heavy chain variable region and light chain variable region.

  本发明旨在提供一种能够与 EphA4 结合并抑制 EphA4 与其配体之间结合的抗 EphA4 抗体或其 EphA4 结合片段，以及一种包含该抗 EphA4 抗体或其 EphA4 结合片段作为活性成分的药物组合物。研究人员获得了对 EphA4 具有结合亲和力的小鼠抗 EphA4 抗体，并确定了小鼠抗 EphA4 抗体的互补性决定区（CDR）序列。这样就可以制备一种人源化抗体，该抗体的重链可变区和轻链可变区都包含小鼠抗 EphA4 抗体的 CDR 序列。